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Onco-Hu™ Models:
Humanized NSG™ and
NSG™-SGM3 Mice for
Immuno-Oncology
ABSTRACT
Understanding the interactions between human
immune cells and tumors is paramount when
devising treatment strategies that prevent tumor
evasion of immune cells and improve cytotoxic
responses. NSG™* and NSG™-SGM3* mice are
a proven host for engraftment of human tumors
or establishment of human immunity following
hematopoietic stem cell transplantation. Here, we
provide evidence that NSG and NSG-SGM3 mice
engrafted with hematopoietic stem cells (collectively
referred to here as “humanized NSG mice”) can
support the growth of allogeneic human tumors.
The human tumors respond to standard-of-care
chemotherapeutics, targeted therapies, and to
immune check-point inhibitors clinically proven
to initiate cytotoxic activity towards the tumor.
Tumor-bearing, humanized NSG mice (the OncoHu™* mouse offered exclusively from The Jackson
Laboratory) are a new and valuable preclinical
testing platform for immuno-oncology.

1

THE JACKSON LABORATORY

*NSG, NSG-SGM3, and Onco-Hu are
trademarks of The Jackson Laboratory.
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Immuno-Oncology:
A New Paradigm
for Patient Care

These results
support the use
of humanized NSG
and NSG-SGM3
mice as a new
preclinical bridge
for immunooncology therapies.

The traditional approach to cancer
treatment utilizes broad-acting
chemical agents that are toxic
to rapidly dividing cells. This
chemotherapeutic approach can
be successful but is complicated
by an array of off-target toxicities
and risks inducing drug resistance.
Targeted therapies are emerging as
new standards-of-care (SOCs) but
often result in resistances that leave
room for improvement. Mammalian
immune systems have efficient,
highly specific mechanisms for
eliminating pathogen-infected cells
and cancerous cells. In response,
tumors have developed their own
suite of mechanisms to evade
immune detection.
Fortunately, researchers are
gaining a better understanding of
the interaction between immune
effector cells and tumors. New,
promising treatment strategies
that stimulate durable, immunemediated tumor regression are now
being used clinically. While these
new immuno-oncology strategies
are highly encouraging, they are not
broadly efficacious across all cancers.
Research to improve immunooncology-based therapies would
benefit from a humanized, small
animal model testing platform. The
platform would allow scientists to
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better understand human immune
and tumor cell interactions and
enable preclinical testing of new
therapies that have a higher
likelihood for clinical success.
Here, we review methods
tumors use to evade immunemediated elimination, current
immunotherapies being tested
in the clinic, and limitations to
developing novel therapies given the
mouse models currently available.
Importantly, we demonstrate the
utility of a new mouse platform−
Onco-hu−that allows the study
of patient-derived xenograft
(PDX) tumors in the context of
a humanized immune system for
immuno-oncology preclinical
research (Figure 1). Humanized NSG
mice (both NSG and NSG-SGM3
hosts) support the growth of PDX
tumors, respond to SOC treatments,
and exhibit immune-mediated tumor
regression following treatment with
a check-point inhibitor. These results
support the use of humanized NSG
mice as a preclinical bridge for new
immuno-oncology therapies.

Tumor Evasion of
Human Immunity
The immune system is a major
regulator of anticancer therapy
response and resistance. Many early
tumors are thought to be eradicated
by host immune cells following
recognition of unique antigens
expressed on the tumor cell’s
surface. Immune cell involvement is
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Figure 1. Onco-Hu: A revolutionary
immuno-oncology mouse platform.
Tumor-bearing humanized NSG mice. CD34+
hematopoietic stem cells are intravenously
injected into sublethally irradiated 3-week
old immunodeficient NSG or NSG-SGM3
mice. After confirmation of human
leukocyte engraftment (including T cells) in
peripheral blood at 15 weeks of age, mice
are then engrafted with patient-derived
xenograft tumors or tumor cell lines. Study
enrollment for immuno-oncology testing
may begin shortly after tumors and reach a
desired size.

largely dictated by tumor type and
molecular signature (Coffelt and
de Visser, 2015). Indeed, advanced
patient-derived tumor samples often
carry human immune effector cells
as passengers. One such population
is tumor infiltrating lymphocytes
(TILs), which are typically CD8+
cytotoxic T lymphocytes (CTLs).
TILs have been isolated from tumors,
expanded ex vivo, and adoptively
transferred back into the patient
to take advantage of their tumorspecific killing ability (Restifo et al.,
2012). The adoptive immunotherapy
approach has been successful
in treating some patients with
metastatic melanoma (Rosenberg
et al., 2011) and has expanded to
the treatment of common epithelial
cancers (Rosenberg and Restifo,
2015). However, it is not universally
effective in eradicating tumors.
The absence or loss of tumor
killing activity, both pre- and postadoptive transfer, can be explained
by multiple modes of immune
suppression.

T lymphocyte antigen 4 (CTLA-4)
and by programmed death 1 (PD-1)
(Ahmadzadeh et al., 2009; Baitsch
et al., 2011). Both are known as
“check-point” pathways because they
prevent the loss of immune tolerance
under normal conditions. Human
monoclonal antibodies Yervoy
(Ipilimumab) and Tremelimumab
have been developed to bind
CTLA-4 and prevent its interaction
with CD80 or CD86 on antigen
presenting cells, causing a block
in T-cell inhibitory signaling. The
current consensus is that CTLA-4
blockade allows CD80 or CD86 to
bind with CD28, thereby activating
a key T-cell co-stimulatory pathway.
Ipilimumab and Tremelimumab
are the first “checkpoint inhibitors”
to advance into clinical trials for
treating melanoma (Pardoll, 2012).
Both antibodies promote longerterm patient survival in a fraction of
patients, a fact that has stimulated
widespread interest to find methods
to activate other native immune
modalities to target tumors.

Two immunosuppressive pathways
that have been implicated in TIL
inhibition are mediated by cytotoxic

PD-1 and its ligand PD-L1 are part
of another key check-point pathway
that has been manipulated to
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enhance CTL-mediated tumor destruction
(Ostrand-Rosenberg et al., 2014; Pauken
and Wherry, 2015). The development of
anti-PD-1 blocking antibodies was spurred
by three key reports: mice with a null
mutation in PD-1 develop an autoimmune
syndrome (Nishimura et al., 1999), TILs
upregulate PD-1 and subsequently become
anergic (Ahmadzadeh et al., 2009), and
many tumor types express PD-L1 (Zou
et al., 2008). In early clinical trials, 28%
of advanced melanoma patients who
were refractory to anti-CTLA-4 antibody
treatment responded to an anti-PD-1
monoclonal antibody (Hamid et al.,
2013). Further, when both anti-PD-1 and
anti-CTLA-4 check-point inhibitors were
combined, 53% of patients responded
favorably (Wolchok et al., 2013).
Immunotherapeutics that inhibit immune
regulatory pathways such as anti-CTLA-4
and anti-PD-1, have initiated a new era
in the treatment of cancer (Coffer and de
Visser, 2015). As of December 2015, there
are over 20 anti-PD-1/PD-L1 antibodies
in clinical trials (Gandini et al., 2016). In
fact, as of 2016, two anti-PD-1 check-point
inhibitors have been approved for the U.S.
market: Prembrolizumab (Keytruda) and
Nivolumab (Optivo). Both are currently
entering clinical trials to test their efficacy

against abroad range of tumor types. Since
CTLA-4 and PD-1 regulate distinct inhibitory
pathways, concurrent combination therapy is
often more efficacious than either treatment
alone (Sharma and Allison, 2015).
Tumors use other mechanisms to evade
immune responses. For example, the highly
inflammatory microenvironment of the
tumor recruits tissue-resident macrophages
and peripheral blood monocytes. These
myeloid cells receive tumor-derived signals
that alter gene expression and phenotype
(Gabrilovich et al., 2012 and Ostuni et al.,
2015). One myeloid cell subpopulation
that develops in the tumor is the tumorassociated macrophages (TAM). TAMs
are an abundant population of leukocytes
in solid tumors. In many settings, TAMs
fuel, rather than limit, tumor progression
(Ostuni et al., 2015). TAMs suppress TIL
activity and increase tumor angiogenesis
by the mechanisms presented in Table 1,
creating a hospitable microenvironment
that favors cancer outgrowth. TAMs also
recruit and stimulate regulatory T cells (Treg)
and T-helper 2 cells (TH2) lymphocytes
contributing to strong immunosuppressive
actions in the tumor. These cells are
normally associated with maintenance of
immune tolerance.

Table 1. Tumor Associated Macrophage (TAM) Immune Suppression
TAM Phenotype

Effect

Increased PD-L1

Suppressed CTL activation

Increased IL-10

Stimulation of TH2 cells

Decreased IL-12

Suppression of T cells

Increased CCL22

Attraction of TReg cells

Increased Tek (TIE2)

Increased angiogenesis
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Table 2. Myeloid Derived Suppressor Cell (MDSC) Immune Suppression
MDSC Phenotype

Effect

Increased ARG1 & NOS2 (iNOS)

Suppressed CTL activation; TCR down-regulation; decreased
proliferation

Increased Reactive Oxygen Species (ROS)

Suppressed CTL activation; TCR down-regulation; decreased IL-2R
signaling

Increased ADAM17

Decreased CD62L on CD4 & CD8 T cells; impaired lymph node
trafficking

Co-stimulation & Soluble factors

Activation and expansion of TReg cells

Other myeloid cells found in tumors
include myeloid-derived suppressor
cells (MDSCs). MDSCs represent a
heterogeneous group of immature cells
that include precursors of macrophages,
granulocytes, and dendritic cells,
defined by their ability to suppress
T cell proliferation and to promote
angiogenesis (Coffelt and de Visser,
2015). As shown in Table 2, MDSCs
use a spectrum of immunosuppressive
mechanisms to help tumors evade
immunity. Most of their effects are
directed at suppressing T cells.
Other immune cell populations
important in tumor immunity include
dendritic cells (DCs) and natural
killer (NK) cells. DCs are considered
“professional antigen presenting cells”
and are capable of processing unique
tumor-specific antigens to activate T
and B cells. DCs, therefore, are at the
center of research devoted to developing
tumor vaccines and to expanding tumorspecific CTLs ex vivo for subsequent
adoptive immunotherapy (Palucka et
al., 2012). NK cells have unique cellsurface receptors that are important
for immune surveillance of self-tissues
and whose activities are mediated
by binding of HLA class I antigenpresenting molecules that are found on
most normal cells and tumors. Tumors
that retain HLA class I expression evade

THE JACKSON LABORATORY

NK cell-mediated cytotoxicity, but
those that lose expression are no
longer recognized by NK cells as
“self” and are killed. Compounds
that promote NK cell activation and
adoptive immunotherapies that use
allogeneic NK cells are active areas of
preclinical and clinical investigation
(Vivier et al., 2012).

New Therapeutics
in the Pipeline
As the information above suggests,
our knowledge of immune cell
function and interactions with tumor
cells is improving. Delineation of
the basic mechanisms that underlie
these interactions has uncovered
several potential strategies through
which immune cells might be
manipulated to enhance their
antitumor activity. Some of the most
promising examples are outlined in
Table 3.
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Table 3. Current Approaches to New Immuno-Oncology Therapeutics
Block ligands & receptors between cells

Monoclonal Antibodies

Bind receptors to activate pathways
Target cells for destruction by ADCC
Antibody-drug conjugates

Bispecific T-cell Engager (BiTE)
Antibodies
Chimeric Antigen Receptors (CARs)

Promotion of T cell killing of target
Promotion of T or NK cell killing of target
Tumor infiltrating lymphocytes (TIL)
TCR gene therapy

Adoptive Cell Transfer

Allogeneic donor lymphocyte infusion (DLI)
Allogeneic NK cell infusion
Antigen loaded dendritic cells

Vaccination

Tumor-specific antigen stimulation

For example, monoclonal antibodies
can block or enhance ligand-receptor
interactions between cells, act as
agonists or antagonists, target cellular
destruction by antibody-dependent
cellular cytotoxicity (ADCC), and deliver
conjugated drug payloads to specific
target cells. Bispecific T-cell Engager
(BiTE) therapy uses binding specificity
regions from two antibodies fused into a
single molecule. These molecules directly
bind CTLs to antigens on tumor cells to
enhance tumor killing (Stone, et al., 2012
and Laszlo et al., 2014).
Additionally, the ability to genetically
engineer lymphocytes to express
conventional T-cell receptors or chimeric
antigen receptors (CARs) has extended
the application of adoptive cell transfer
immunotherapies (Rosenberg and
Restifo, 2015). CAR T-cell therapy is
an exciting and powerful technology
that was designated as a Breakthrough
Therapy in 2014 by the U.S. Food and
Drug Administration (FDA). A CAR is
composed of the antigen-recognition
portion of an antibody conjugated to the
transmembrane and signaling domains
of a T-cell receptor. When expressed
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on T-cells isolated from a patient,
CARs recognizing cancer-associated
antigens can be infused back into the
bloodstream. Such CAR T-cells have
the ability to decrease tumor burden
and increase survival. CAR T-cell
therapy has made great strides in
treating CD19 positive leukemias and
lymphomas which have previously
failed all other chemotherapeutic
interventions (Dai, et al., 2016).
Future developments in CAR therapy
will focus on the unique barriers to
treating solid tumors, expressing
CARs in NK cells, and combination
therapies with check-point inhibitors
(Beavis et al., 2015, Vanneman and
Dranoff, 2012, Rezvani et al., 2015,
and John et al. 2013).
Allogeneic (i.e., mismatched)
donor lymphocyte infusion (DLI)
creates a graft-versus-tumor effect
and has been successful in treating
many patients with leukemia. A
similar approach is being explored
using allogeneic NK cells (Vivier
et al., 2012). Greater knowledge of
tumor-specific antigens has been
accumulating such that tumor
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antigen peptides might be used to
prime DCs and thereby stimulate their
adaptive immune responses prior to
adoptive transfer. Alternatively, these
antigens might be injected directly as
potential vaccines to amplify endogenous
tumor-specific T-cell responses (Miller
and Sadelain, 2015). All of these new
approaches require appropriate in vivo
preclinical evaluation prior to testing
in humans in order to validate their
mechanism of actions, efficacy, and
safety.

The Challenge of
Developing New
Therapeutics
Laboratory mice represent one of
the most valuable research platforms
for characterizing in vivo immunetumor interactions and for testing
new therapeutics. Immune-competent
mice can be genetically engineered
to develop tumors spontaneously, or
can be transplanted with tumors from
a syngeneic donor or tumor cell line.
Mouse genetics, immunity, and tumor
development share many similarities
with humans, but distinct differences
exist. For example, humans and mice
differ in peripheral blood lymphocyte
distribution and their neutrophils
respond differently in innate and
adaptive immune stimulation (Mestas
and Highes, 2004). MDSCs in mice are
primarily of the less-immunosuppressive
polymorphonuclear variety, while those
in humans are commonly the more
suppressive monocytic type (Gabrilovich
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et al., 2012). The etiology of tumor
development in the two species
is also not necessarily identical
(Rangarajan and Weinberg, 2003).
Additionally, mice and humans
exhibit differences in receptorligand homologies and affinities
such that reagents showing efficacy
in the mouse do not necessarily
show the same efficacy in the clinic.
Inbred mice, also, are genetically
uniform, which greatly enhances
their scientific utility with respect
to drug specificity and therapeutic
reproducibility, but humans are
genetically diverse. Human genetic
diversity can dilute efficacy or
uncover previously unobserved
off-target toxicities. In some cases, a
therapeutic developed in the mouse
may need to be re-engineered and
re-tested in a more human-specific
system. Such efforts can be expensive
and time-consuming.
Given the challenges of testing
novel immuno-oncology therapies
in mice, researchers at The Jackson
Laboratory have employed a highly
immunodeficient mouse, called
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ,
005557), that is capable of engrafting
human hematopoietic stem cells
and supports the development
and function of multiple aspects
of human immunity (jax.org/
humanized-mice).
In addition, JAX In Vivo
Pharmacology Services has recently
expanded its humanized mouse
models by employing a new NSG
variant, NSG-SGM3 (NOD.CgPrkdcscid Il2rgtm1Wjl Tg(CMV-IL3,
CSF2, KITLG)1Eav/MloySzJ,
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013062). NSG-SGM3 mice are NSG
mice that express human hematopoietic
cytokines: stem cell factor (SCF),
also known as Steel Factor gene and
Kit Ligand, granulocyte/macrophagestimulating factor (GM-CSF), and
interleukin-3 (IL-3), all driven by a
human cytomegalovirus promoter/
enhancer sequence. Triple transgenic
NSG-SGM3 mice constitutively produce
2-4 ng/ml serum levels of human
SCF, GM-CSF, and IL-3, providing
cell proliferation and survival signals
that become more measurable over
time. These mice support the stable
engraftment of CD33+ myeloid lineages,
and several types of lymphoid cells. As a
result, NSG-SGM3 mice allow superior
engraftment of diverse hematopoietic
lineages compared to other existing
models.
Both NSG and NSG-SGM3 mice
support co-engraftment of both human
immune cells and a wide range of
human PDX tumors. We demonstrate
that PDX tumors grown in the context
of humanized immune systems respond
to standard-of-care chemotherapeutics
and to the checkpoint inhibitor Keytruda
(Prembrolizumab), establishing
humanized NSG mice as a new
preclinical platform for testing humanspecific immuno-oncology therapeutics.

THE JACKSON LABORATORY

Meeting the Need
with NSG and
NSG-SGM3 Mice
At The Jackson Laboratory,
humanized mice are created by first
sub-lethally irradiating NSG (huCD34-NSG™) or NSG-SGM3 (huCD34-NSG™-SGM3) mice at 3-4
weeks of age, followed by subsequent
tail vein injection of human CD34+
HSCs isolated from cord blood.
Peripheral blood (PBL) engraftment
is validated 12 weeks later. NSG mice
support multi-lineage engraftment
and human immune cell homing into
nearly all of the appropriate organs
and tissues, including host bone
marrow, thymus, spleen, and PBL (as
summarized in Figure 2 and Table 4,
Ishikawa et al., 2005; Tanaka et al.,
2012).
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A. Bone Marrow

Among hu-CD45+ cells

Figure 2. Humanized CD34+
NSG mice support multilineage
engraftment of human cells,
including B cells, T cells, dendritic
cells and monocytes.
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Among hu-CD3+ cells

Lymphoid Cells

Macrophages

CD4+ & CD8+ T cells

Monocytes

TReg

Neutrophils

B cells

Basophils

NK cells

Table 4. Human MultiLineage Engraftment in
hu-CD34-NSG
Data provided by JAX® In Vivo
Pharmacology Services, The
Jackson Laboratory.

Mast cells
Erythroid progenitors
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Compared to the humanized NSG™
model, humanized NSG™-SGM3
mice have increased cell counts
of the following human immune
cell populations (as summarized
in Figure 3, and Wunderlich et al.,
2010; Billerbeck et al., 2011)
•

CD33+ myeloid cells

•

Hematopoietic stem cells

•

Myeloid progenitor cells

•

Mast cells

•

Myeloid dendritic cells

•

T cells (CD3+)

•

T helper cells (CD4+)

•

T cytotoxic cells (CD8+)

•

T regulatory cells (CD4+,
CD25+, FoxP3+)

Figure 3. Comparison in
engraftment between NSG and
NSG-SGM3 (cells/μL) as measured
in peripheral blood.
(A) Total huCD45+ donor cell count, (B)
Total huCD33+ myeloid cell count, (C) Total
huCD19+ B cell count, (D) Total huCD3+
T cell count, (E) Total huCD3+CD8+ T
cell count, and (F) Total huCD3+CD4+ T
cell count. Data provided by JAX® In Vivo
Pharmacology Services, The Jackson
Laboratory.
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T Cells
In addition to human immune cell
development, hu-CD34-NSG have been
functionally validated. In particular,
immature human T-cell progenitors
(CD4+ CD8+ double positive cells)
produced in the bone marrow of huCD34-NSG mice are found in the thymus
along with mature CD4+ and CD8+
single positive T cells (Ishikawa et al.,
2005). The mature CD4+ T-helper
cells and CD8+ CTLs then leave the
thymus and populate the PBL and spleen.
Together, these observations demonstrate
that the cells are undergoing thymic
TCR selection (self-versus-non-self) and
homing to appropriate tissues.
To confirm the cytotoxic activity of the
human T cells, these cells were harvested
from the spleens of engrafted mice,
expanded clonally ex vivo by growth
with allogeneic target cells, and then
challenged with allogeneic target cells
in a chromium release cytotoxicity assay
(Ishikawa et al., 2005). CD4+ T cells
recognized targets in the context of class
II antigens and CD8+ T cells recognized
targets in the context of class I antigens,
as expected of normal, mature human T
cells.
Hu-CD34-NSG mice also demonstrate
delayed-type hypersensitivity (DTH),
another measure of T cell function.
In this assay, hu-CD34-NSG mice
were sensitized with two abdominal
applications of dinitrofluorobenzene
(DNBF) and one week later were
challenged by topical application of
DNBF to the ear pinna. An in vivo T cell
mediated pro-inflammatory response was
observed by measuring the swelling of

THE JACKSON LABORATORY

the pinna. Moreover, this response
was blocked by hydrocortisone (JAX
In Vivo Pharmacology Services; data
not shown).

B Cells
In addition to T cell function, B cell
function in hu-CD34-NSG mice
was examined by immunization
with ovalbumin to stimulate
immunoglobulin production.
The human B cells responded by
producing ovalbumin-specific IgM
but only minimal IgG (Ishikawa et
al., 2005). A current limitation of
this platform is a paucity of human
cell populations within peripheral
lymph nodes and poor development
of germinal centers. These both
are necessary for the development
of the memory and plasma B cells
that are responsible for robust
immunoglobulin class switching to
IgG. Additionally, NSG mice are C5
complement deficient. Although the
absence of hemolytic complement
activity supports more robust human
cell engraftment in NSG, it prevents
complement dependent cytotoxicity
(CDC) responses stimulated by
antibody binding to target cells.

Myeloid Cells
The hu-CD34-NSG mice also
develop the full spectrum of myeloid
cell lineages with their appropriate
functional activities (Tanaka et al.,
2012). Human macrophages isolated
from the bone marrow and lung
of engrafted mice are capable of
phagocytosis of fluorescent beads

JAX® MICE, CLINICAL AND RESEARCH SERVICES
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and are cytotoxic to S. typhimurium
when stimulated with interferon gamma
(INF-γ). Macrophages develop proinflammatory responses to bacterial
lipopolysaccharides (LPS) through Tolllike receptors. The human monocytes/
macrophages in hu-CD34-NSG express
TLR2 and TLR4, and when the mice are
challenged with LPS, multiple human
pro-inflammatory molecules are detected
in plasma, demonstrating an in vivo
functional response (Tanaka et al., 2012).
Neutrophils play an important role in
innate immunity and in tumor biology,
by developing into MDSC. Human
neutrophils, defined by the markers
CD15+, CD33 low, and HLA-DR-,
represent 35% of the human cells in bone
marrow and 1-5% in the spleen of huCD34-NSG mice (Tanaka et al., 2012).
Human CD66b+ neutrophils account for
less than 1% in PBL but increase to 2.6%
after in vivo treatment with granulocyte
colony stimulating factor (Coughlin et
al., 2012). The marker CD63 is expressed
in azurophilic granules of neutrophils,
and human neutrophils in mice treated
with LPS increase CD63 expression,
indicating degranulation activity. LPS
also stimulates an increased respiratory
response and causes human neutrophils
to accumulate in the lung, mimicking
bacterial-induced sepsis. These results
demonstrate the human neutrophils in
hu-CD34-NSG mice are functional.

2010). The majority of these NK
cells are immature NKp46+ CD56cells, but they can be induced to
mature into NKp46+CD56+ cells
when treated with interleukin 15
(IL-15). Human NK cells isolated
from hu-CD34-NSG spleens degranulate and produce IFN-γ in
vitro when treated with IL-15 and
provided K562 cells as targets. K562
is a human erythroleukemia cell
line that expresses NK recognition
molecules NCR, NKG2D, and
DNAM. These data provide evidence
that humanized NSG mice produce
NK cells that can be activated and
respond to cells recognized as nonself.
Given the abundance of functional
human immunity reported in the
hu-CD34-NSG mice, it was predicted
that these mice would rapidly reject
any non-HLA matched human
PDX tumor that was co-engrafted
subcutaneously. As described above,
however, there is ample published
evidence for multiple mechanisms
by which tumors evade immunity.
The following data provide clear
evidence that hu-CD34-NSG mice
can efficiently engraft both human
cancer cell lines and diverse human
PDX tumors that are not HLA
matched to the hematopoietic donor
cells used to humanize the NSG host.

Natural Killer Cells
Lastly, hu-CD34-NSG mice have CD3NKp46+ NK cells that represent 1-3%
and 7% of human cells in the spleen
and lung, respectively (Strowig et al.,
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These results demonstrate that huCD34-NSG mice support non-HLA
matched tumor growth and that the
presence of human immune cells does
not significantly impact tumor take or
growth rates.

breast (TM00090), [B] lung (TM00213), and [C] sarcoma
(TM00381) PDX grew at similar rates in NSG and humanized
NSG recipients. PDX tumors were not HLA matched to the
donor hematopoietic cells. Data provided by JAX® In Vivo
Pharmacology Services, The Jackson Laboratory.
A. Breast
Tumor Growth Curve in NSG Mice vs. Hu-NSG Mice
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Initial experiments evaluated whether
human tumors would grow in humanized
NSG mice that had been engrafted
with allogenic human HSC. Breast,
lung, and sarcoma PDX tumors were
implanted subcutaneously into NSG or
hu-CD34-NSG mice with established
and functionally mature human immune
cells derived from an HLA mismatched
human HSC donor (Figure 4). All three
tumors showed robust growth and no
obvious indication of rejection. At study
termination, tumors were analyzed by
flow cytometry for the presence of TILs.
Interestingly, all three tumors contained
human CD4+ and CD8+ T cells, but few
CD19+ B cells were detected (Figure
5). The failure of the TILs to slow tumor
growth in the hu-CD34-NSG recipients
suggests that these T-cells may have
become anergic, similar to strategies
tumors use to evade human immunity, as
described above.

Figure 4. Presence of human immunity does
not impact human tumor growth. [A] Human
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C. Sarcoma
Tumor Growth Curve in NSG Mice vs. Hu-NSG Mice
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% of Lymphocytes in Hu-CD45+ Cells

A. Breast
Figure 5. PDX tumors grown in hu-CD34-NSG mice
contain tumor infiltrating lymphocytes. [A] Human breast

Human TILs in PDX Tumors

100

(TM00090), [B] lung (TM00213), and [C] sarcoma (TM00381) PDX
contain CD4+ and CD8+ T-cells, but minimal CD19+ B cells. The
presence of TILs did not appear to influence tumor growth. Data
provided by JAX® In Vivo Pharmacology Services, The Jackson
Laboratory.
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C. Sarcoma

Human Tumors
in Onco-Hu Mice
Respond to Therapy
The ability of the humanized NSG
mice to support the growth of nonHLA matched human tumors was an
important finding in the development of
this preclinical testing platform. Next, we
asked whether engrafted tumors would
respond to clinically relevant standardof-care (SOC) treatments and whether
immuno-oncology checkpoint inhibitors
could reactivate anti-tumor responses in
the resident human immune cells.
In a first set of experiments, allogenic
human breast cancer PDX tumor
fragments, which exhibited PD-L1 cell
surface expression on 56.9% of cells
by flow cytometry, were engrafted
into hu-CD34-NSG or hu-CD34-NSGSGM3 mice and were subsequently
treated with vehicle, SOC treatments
(Cisplatin or Doxorubicin), or PD-1
inhibitor, Keytruda (Figure 6). Cisplatin,
Doxorubicin, and Keytruda significantly
reduced tumor growth compared to the
vehicle control, indicating that both SOC
and novel immunotherapeutics show
efficacy in tumor-bearing hu-CD34-NSG
and hu-CD34-NSG-SGM3 mice.
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A.

Figure 6. PD-L1 expressing
allogenic PDX triple negative
breast cancer responds to
standard of care therapy and
Keytruda.

B.

THE JACKSON LABORATORY

Human PDX breast tumor (model
TM00098) grown in either hu-C34
NSG (A) or hu-CD34-NSG-SGM3
mice (B) were treated with either
standard of care therapies (Cisplatin
or Doxorubicin, as indicated in figure)
or Keytruda and compared to vehicle
group. P<0.05 by one-way ANOVA
followed by Dunnett’s Multiple
Comparison Test.
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Similar experiments were performed
using allogenic human non-small cell
lung cancer (NSCLC) PDX fragments,
which exhibited PD-L1 cell surface
expression on 89.1% of cells by flow
cytometry (Figure 7). These PDX tumors
were engrafted into hu-CD34-NSG and
hu-CD34-NSG-SGM3 mice and treated
with vehicle, SOC, Keytruda or CTLA-4
inhibitor, Yervoy. As before, both SOC
and check-point inhibitors significantly
reduced tumor growth compared to the
vehicle control. In the hu-CD34-NSG
mice, NSCLC PDX tumors were collected
at study completion and analyzed by
immunofluorescence. CD8+ T-cells
had infiltrated Keytruda-treated tumors
indicating that tumor regression may be
mediated by cytotoxic T-cells (data not
shown).

A.

Together, these experiments demonstrate
that human tumors engrafted in huCD34-NSG and hu-CD34-NSG-SGM3
mice are able to respond to standard-ofcare chemotherapeutics. An even more
significant finding, however, is that the
engrafted tumors appear to evade human
immunity much as they do in the patients
from which they were derived. Moreover,
treatment with a TIL check-point inhibitor
presumably releases T-cells from anergy
and stimulates their cytotoxicity towards
the tumor. These are all very preliminary
experiments and additional work is needed
to verify the increased TIL-mediated
cytotoxicity in the Keytruda-treated samples.
Nevertheless, these data clearly show the
hu-CD34-NSG and hu-CD34-NSG-SGM3
mice as powerful platforms for gathering
new insights into the interactions of
human immune cells and tumors and for
testing immuno-oncology and combination
therapies.
B.

Figure 7. Allogenic non-small cell lung cancer (NSCLC) PDX responds to checkpoint
inhibitor blockade and increases tumor infiltration of cytotoxic T-cells.
Human PDX lung tumor (model TM00302) grown in either hu-CD34-NSG (A) or hu-CD34-NSG-SGM3 mice (B)
were treated with either standard of care therapy (Cisplatin) or checkpoint inhibitors (Keytruda or Yervoy) and
compared to vehicle group.
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Accessing
Humanized Mice,
Onco-Hu, and PDX
Tumors
Obtaining access to human sources of
hematopoietic stem cells and tissues
remains a strong barrier to widespread
access and construction of these valuable,
humanized animal models. Similarly,
HSC quality can vary considerably from
donor-to-donor, which can significantly
impact engraftment efficiency and,
ultimately, the quality of the humanized
mice created. To assist scientists in
gaining ready access to these humanized
models, The Jackson Laboratory has
developed our humanized mice resource
through which we can provide:
•

Study-ready cohorts of inventoried
hu-CD34-NSG and hu-CD34-NSGSGM3 mice for immediate shipment
to your institution.

•

NSG mice engrafted with human
peripheral blood mononuclear cells
(hu-PBMC NSG and hu-PBMC NSGSGM3 mice).

•

Onco-Hu mice, humanized NSG and
NSG-SGM3 mice engrafted with
PDX tumors.

•

Customized drug efficacy studies
executed by our In Vivo Services
scientists.

The hu-PBMC NSG and hu-PBMC
NSG–SGM3 mice have not been tested
for growth of human tumors, but may
prove equally important in developing

THE JACKSON LABORATORY

immuno-oncology-based therapies
for aggressive hematological
cancers such as AML and other
leukemias (Theocharides et al 2016).
Humanized mice from The Jackson
Laboratory can be imported directly
into your facility and used in your
experiments following a standard
1-2 week acclimation period. The
engrafted human HSCs are tested
and free of HIV, Hepatitis B Virus
(HBV), Hepatitis C Virus (HCV),
and lymphocytic choriomeningitis
virus (LCMV).
Further, The Jackson Laboratory has
partnered with 25 cancer clinics
nation-wide to provide access to a
variety of patient-derived xenograft
cancer models at earlier passage
stages than any other commercial
PDX repository. Currently, more
than 400 unique PDX oncology
models from either treatment-naive
or treatment-resistant patients
have been established in the highly
immunodeficient NSG mouse
strain (Figure 8). NSG mice engraft
primary human tumors that at
low passage retain the genetic and
phenotypic heterogeneity typically
seen in human cancers, offering a
distinct advantage over other PDX
hosts. This preclinical platform can
predict the effectiveness of novel
therapeutics to treat cancer patients.
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Perfoming Efficacy
Studies Using New
Immunotherapeutics
The Jackson Laboratory can provide
you with experimental cohorts of any
of our PDX cancer models engrafted in
NSG mice or in humanized NSG mice.
Alternatively, our Ph.D.-trained study
directors can conduct either standardized
or fully customizable efficacy studies
using these models for you at our facility.
Typical studies that we perform may
include pilot oncology or immuno-oncology
efficacy studies for single or combination
drug dosing, dose-response relationship
analyses, or compound tolerability studies.
To assist you in selecting a tumor model,
detailed descriptions of our PDX tumors
are available from the Patient Derived
Xenograft Search Form on the Mouse
Tumor Biology website: (tumor.informatics.
jax.org).
The idea of harnessing immune cells to fight
cancer is not new, but only in the past few
years have scientists demonstrated what a
game-changer cancer immunotherapy can
be in the clinic (Mueller 2015). Currently,
only a subset of patients responds to
immunotherapy. It is critical to understand
why. Tumor-bearing humanized NSG and
NSG-SGM3 mice are a valuable preclinical
testing platform to address outstanding
questions in this rapidly advancing
field: 1) Which tumor types will be most
responsive to immunotherapy and what
are the underlying mechanisms? 2) How
can optimal therapy combinations be
determined for individual patients? 3) What
are the mechanisms behind resistance to
immunotherapy and immunomodulatory
agents? 4) How can resistance be
anticipated and prevented? New insights
will forge the way towards improving
existing therapies and developing new
approaches.
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Figure 8. PDX tumor types available from The Jackson
Laboratory. Over 400 low passage tumors have been collected and
grown in NSG mice. Tumors are characterized for gene expression, gene
deletion, and copy number variation. Growth characteristics and histology
are available, also.
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